{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-22-000055","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.831364+00:00","generated_at":"2026-06-22T09:30:06.929594+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"KB407 CF gene therapy data: human CFTR expression 106–440% of endogenous in NHPs; IND accepted","bullets":["KB407 transduced ciliated, club, and goblet cells in NHP airways; no transduction of basal cells.","Human CFTR transcript levels reached 106–440% of endogenous NHP CFTR in lung biopsies.","No adverse findings in GLP toxicology study; NOAEL at highest dose tested.","FDA accepted KB407 IND in July 2022.","No significant cytokine induction in human CF cells after KB407 transduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-22-000055","json":"https://secwatch.observer/filing/0001711279-22-000055.json","markdown":"https://secwatch.observer/filing/0001711279-22-000055.md","text":"https://secwatch.observer/filing/0001711279-22-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000055/0001711279-22-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000055/krys-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:30:06.929594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}